Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/new-targeted-agents-in-gastroenteropancreatic-neuroendocrine-tumors-4M6dmOgRVV
References (33)
-
James Yao, A. Phan, P. Hoff, Helen Chen, C. Charnsangavej, S. Yeung, K. Hess, C. Ng, J. Abbruzzese, J. Ajani (2008)
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
-
Florian Bösch, Christoph Auernhammer, Christine Spitzweg, Martin Angele (2019)
Gastroenteropancreatic Neuroendocrine TumoursGastroenterology For General Surgeons
-
JC Yao, C Lombard-Bohas, E Baudin (2010)
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol, 28
-
James Yao, A. Phan, D. Chang, R. Wolff, K. Hess, Sanjay Gupta, C. Jacobs, J. Mares, A. Landgraf, A. Rashid, F. Meric-Bernstam (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 26
-
R. García-Carbonero, R. Salazar, I. Sevilla, D. Isla (2011)
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)Clinical and Translational Oncology, 13
-
J. Phan, A. Mazloom, L. Medeiros, T. Zreik, Christine Wogan, F. Shihadeh, M. Rodriguez, L. Fayad, N. Fowler, V. Reed, Patrecia Horace, B. Dabaja (2010)
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 27
-
M. Guba, P. Breitenbuch, M. Steinbauer, G. Koehl, Stefanie Flegel, M. Hornung, C. Bruns, C. Zuelke, S. Farkas, M. Anthuber, K. Jauch, E. Geissler (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 8
-
Y. Jiao, C. Shi, B. Edil, R. Wilde, D. Klimstra, A. Maitra, R. Schulick, Laura Tang, elliot fishman, M. Choti, V. Velculescu, L. Diaz, B. Vogelstein, K. Kinzler, R. Hruban, N. Papadopoulos (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 331
-
P. Oberstein, M. Saif (2012)
Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine TumorsClinical Medicine Insights. Oncology, 6
-
Jun Zhang, Z. Jia, Qiang Li, Liwei Wang, A. Rashid, Zhenggang Zhu, Douglas Evans, J. Vauthey, K. Xie, James Yao (2007)
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression‐free survival among patients with low‐grade neuroendocrine tumorsCancer, 109
-
Yi-Zarn Wang, Saju Joseph, Erika Lindholm, J. Lyons, J. Boudreaux, Eugene Woltering (2010)
Lymphatic Mapping Helps Define Resection Margins for Midgut CarcinoidsPancreas, 39
-
IM Modlin, K Oberg, DC Chung (2008)
Gastroenteropancreatic neuroendocrine tumoursLancet Oncol, 9
-
M. Kulke, H. Lenz, N. Meropol, J. Posey, D. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, Xin Huang, Jim Li, C. Baum, C. Fuchs (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 20
-
K. Öberg (2009)
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)Current Opinion in Endocrinology, Diabetes and Obesity, 16
-
Jaume Capdevila, A. Teule, D. Castellano, Javier Sastre, Rocio Garcia-Carbonero, I. Sevilla, I. Duran, Pilar Escudero, José Fuster, E. Pulido (2011)
PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
S. Faivre, C. Delbaldo, K. Vera, C. Robert, Stéphanie Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J. Armand, P. Scigalla, E. Raymond (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 1
-
James Yao, A. Phan, D. Fogleman, C. Ng, C. Jacobs, C. Dagohoy, C. Leary, K. Hess (2010)
Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker.Journal of Clinical Oncology, 28
-
A. Phan, James Yao, D. Fogelman, K. Hess, C. Ng, S. Bullock, P. Malinowski, E. Regan, M. Kulke (2010)
A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).Journal of Clinical Oncology, 28
-
T. Hobday, J. Rubin, K. Holen, J. Picus, R. Donehower, R. Marschke, W. Maples, R. Lloyd, M. Mahoney, C. Erlichman (2007)
MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) studyJournal of Clinical Oncology, 25
-
A. Moreno, A. Akcakanat, M. Munsell, Alpana Soni, James Yao, F. Meric-Bernstam (2007)
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.Endocrine-related cancer, 15 1
-
H. Dvorak (2002)
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
-
I. Durán, J. Kortmansky, Darshan Singh, H. Hirte, W. Kocha, G. Goss, L. Le, A. Oza, T. Nicklee, J. Ho, D. Birle, G. Pond, D. Arboine, J. Dancey, S. Aviel‐Ronen, M. Tsao, D. Hedley, L. Siu (2006)
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 95
-
K. Pietras, D. Hanahan (2005)
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
-
James Yao, M. Shah, Tetsuhide Ito, C. Bohas, E. Wolin, E. Cutsem, T. Hobday, T. Okusaka, J. Capdevila, E. Vries, P. Tomassetti, M. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Öberg (2011)
Everolimus for advanced pancreatic neuroendocrine tumors.The New England journal of medicine, 364 6
-
K Oberg (2009)
Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumorsCurr Opin Endocrinol Diabetes Obes Feb, 16
-
James Yao, Manal Hassan, A. Phan, Cecile Dagohoy, C. Leary, J. Mares, E. Abdalla, J. Fleming, J. Vauthey, A. Rashid, Douglas Evans (2008)
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
-
F. Meric-Bernstam, A. González-Angulo (2009)
Targeting the mTOR signaling network for cancer therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 13
-
R. García-Carbonero, J. Capdevila, G. Crespo-Herrero, J. Díaz-Pérez, M. Prado, V. Orduña, I. Sevilla-García, C. Villabona-Artero, A. Beguiristain-Gómez, M. Llanos-Muñoz, Mónica Marazuela, C. Alvarez-Escola, D. Castellano, Eduardo Vilar, P. Jiménez-Fonseca, A. Teule, J. Sastre-Valera, M. Benavent-Viñuelas, A. Monleón, R. Salazar (2010)
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).Annals of oncology : official journal of the European Society for Medical Oncology, 21 9
-
M. Pavel, J. Hainsworth, E. Baudin, M. Peeters, D. Hörsch, R. Winkler, J. Klimovsky, D. Lebwohl, V. Jehl, E. Wolin, K. Öberg, E. Cutsem, James Yao (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyThe Lancet, 378
-
E. Raymond, L. Dahan, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, Denis Smith, A. Vinik, Jen‐Shi Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Cutsem, S. Patyna, D. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski (2011)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.The New England journal of medicine, 364 6
-
Fynn Rw (1959)
One hundred years after.The Central African journal of medicine, 5
-
D Castellano, J Capdevila, R Salazar (2010)
Neuroendocrine tumorsAnn Oncol, 21
-
D. Hicklin, L. Ellis (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer-Verlag
- Subject
- Medicine & Public Health; Oncology; Biomedicine general
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-012-0218-9
- pmid
- 22585431
- Publisher site
- See Article on Publisher Site
Abstract
Neuroendocrine carcinomas are rare neoplasms although of increasing incidence and concern. While traditionally considered of indolent nature, once they progress beyond surgical resectability, the outcome is ultimately fatal for the majority of patients. Somatostatin analogs are useful to control symptoms in functioning tumors and may slow tumor progression in certain disease settings, but sensitivity to conventional cytotoxic chemotherapy is rather limited. In this context, results of the recently published randomized trials with sunitinib and everolimus have demonstrated for the first time that there are agents able to positively impact on the natural history of this complex disease. In this review, we will discuss available data on angiogenesis and mammalian target of rapamycin inhibitors for the treatment of advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Journal
Targeted Oncology – Springer Journals
Published: May 15, 2012